Heterotandem bicyclic peptide complex
US11312749B2 · kind B2 · utility
13Cited by
2References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 29, 2020 |
| Grant date | Apr 26, 2022 |
| Priority date | — |
| Expiry date | Jul 29, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to EphA2, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.